BSN Tracker

tirzepatide

Brand: Mounjaro, Zepbound

⚠ BBW Prototype Drug
Drug Class: dual GLP-1/GIP receptor agonist (twincretin)
Drug Family: antidiabetic
Subclass: dual incretin receptor agonist
Organ Systems: endocrinecardiovascular

Mechanism of Action

First-in-class dual agonist of both GLP-1 and GIP receptors. GLP-1R activation reduces glucagon and stimulates glucose-dependent insulin secretion; GIP receptor activation further enhances insulin secretion, reduces gluconeogenesis, and synergistically reduces appetite. The combined activation produces greater HbA1c reductions and weight loss than any single incretin agonist.

GLP-1 receptor (GLP-1R)GIP receptor (GIPR)

Indications

  • type 2 diabetes mellitus (Mounjaro)
  • chronic weight management in obesity (Zepbound)

Contraindications

  • personal or family history of medullary thyroid carcinoma
  • MEN2
  • pregnancy

Adverse Effects

Common

  • nausea
  • diarrhea
  • vomiting
  • constipation
  • abdominal pain

Serious

  • pancreatitis
  • medullary thyroid carcinoma (rodent data)
  • cholelithiasis
  • hypoglycemia (with sulfonylureas or insulin)
  • tachycardia

Pharmacokinetics (ADME)

Absorption subcutaneous once-weekly injection
Distribution Vd ~10.3 L (albumin-bound via fatty acid chain)
Metabolism proteolytic catabolism; partial amide hydrolysis
Excretion proteolytic degradation products renally excreted
Half-life 5 days
Onset days to weeks
Peak 8–72 hours
Duration 7 days
Protein Binding >99% (albumin)
Vd 10.3 L

Drug Interactions

Drug / Agent Mechanism Severity
oral contraceptives gastric emptying delay reduces Cmax of OCP; backup contraception recommended moderate
sulfonylureas / insulin additive hypoglycemia risk; consider dose reduction of secretagogue major

Nursing Considerations

  1. Inject subcutaneously once weekly; may rotate between abdomen, thigh, or upper arm sites.
  2. Titrate dose slowly every 4 weeks (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg) to minimize GI adverse effects.
  3. Advise patients that weight loss outcomes are superior to all other agents: SURMOUNT-1 trial showed mean 20.9% weight loss at 72 weeks.
  4. Counsel patients starting hormonal contraceptives to use backup contraception for 4 weeks after each dose increase.

Clinical Pearls

  • Tirzepatide represents the most potent glucose-lowering and weight-loss pharmacotherapy available as of 2024–2025, with phase 3 trials showing HbA1c reductions of 2.0–2.3% and weight losses of 15–20% — superior to any prior single agent.
  • The dual GIP/GLP-1 agonism is clinically meaningful: GIP receptors in the CNS and adipose tissue synergize with GLP-1 signaling to produce additive metabolic effects not achievable with GLP-1 agonism alone.

Safety Profile

Pregnancy contraindicated
Lactation avoid
Renal Adjustment Not required
Hepatic Adjustment Not required
TDM Not required
Guideline Update pending

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.

Chronic Weight Management In Obesity (Zepbound) Dual GLP-1/GIP Receptor Agonist (twincretin) Type 2 Diabetes Mellitus (Mounjaro)
← Back to Medications